PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 186 filers reported holding PDL BIOPHARMA INC in Q3 2017. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $127,000 | -38.3% | 40,402 | -42.8% | 0.00% | -33.3% |
| Q2 2020 | $206,000 | -44.3% | 70,622 | -38.0% | 0.00% | +50.0% |
| Q4 2019 | $370,000 | -35.3% | 113,986 | -56.9% | 0.00% | -60.0% |
| Q3 2019 | $572,000 | +20.7% | 264,622 | +75.2% | 0.01% | 0.0% |
| Q2 2019 | $474,000 | -7.4% | 151,020 | +9.6% | 0.01% | 0.0% |
| Q1 2019 | $512,000 | +232.5% | 137,734 | +158.9% | 0.01% | +150.0% |
| Q4 2018 | $154,000 | -31.6% | 53,195 | -37.8% | 0.00% | -33.3% |
| Q3 2018 | $225,000 | -40.0% | 85,543 | -46.6% | 0.00% | -40.0% |
| Q2 2018 | $375,000 | +11.3% | 160,075 | +39.6% | 0.01% | 0.0% |
| Q1 2018 | $337,000 | +287.4% | 114,700 | +261.3% | 0.01% | +150.0% |
| Q4 2017 | $87,000 | +10.1% | 31,746 | +36.8% | 0.00% | 0.0% |
| Q3 2017 | $79,000 | -66.5% | 23,214 | -79.2% | 0.00% | -80.0% |
| Q4 2016 | $236,000 | +237.1% | 111,390 | +435.5% | 0.01% | +100.0% |
| Q3 2016 | $70,000 | -59.5% | 20,800 | -57.6% | 0.01% | -73.7% |
| Q4 2015 | $173,000 | – | 49,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |